Transplanted kidney loss during colorectal cancer chemotherapy: A case report

Table 2 Clinical characteristics of kidney transplant patients treated with adjuvant (n = 7) and palliative chemotherapy (n = 5) for colorectal cancer

Refs	Patients	Sex	Age at diagnosis, yr	Clinical stage	Chemotherapy	Cycles	Graft loss	ADR	Response	DFS/PFS (mo)	OS (mo)
Kim et al[5]	5 of 171	6 W, 11 M	54 ± 7	Stage 0 (n = 2)			Yes, 2 (within 1 yr)			25.1 ± 9.2
				Stage I (n = 5)
				Stage II (n = 3)	FU-LV (n = 1)	12		NS			NA
				Stage III (n = 3)	Capecitabine (n = 2)	12		NS			25
				Stage IV (n = 4)	Capecitabine (n = 1); FU-LV (n = 1)	812		NS			10
Fang[20]	1	M	36	Stage II (pT3N0M0)	FOLFOX	3	No	NS	PD	0	NA
Liu et al[24]	2	M	44	Stage II (pT3N0M0)	Capecitabine	8	No	NA	SD	NA	Alive after 21
		M	54	Stage II (pT3N0M0)	Capecitabine	8	No	NA	SD	NA	Alive after 8
Xia et al[25]	1	M	51	Stage III B (pT3N1M0)	FOLFOX	8	No	NS	PR	NA	NA
Liu et al[24]	1	M	68	Stage III (pT4N1M0)	Capecitabine (after progression)	3	No	NS	PR	2	4-5 for CTH
Müsri et al[26]	1	M	64	Stage IV	FOLFIRI + bevacizumab	5	NS	Proteinuria	PR (regression of liver metastasis)	NA	NA
								Deterioration of kidney function
Bellyei et al[19]	1	M	66	Stage IV	FOLFIRI + cetuximab	1	No	Blood sugar level fluctuation	NA	NA	NA
								Diarrhea
								Hypomagnesemia
					FOLFIRI + panitumumab	3	No	Weight loss	PR(paraaortic lymph node regression)	NA	NA
								Diarrhea
								Hypomagnesemia
					SBRT + panitumumab	16	No	Skin rash	CR	NA	NA-stroke
								Hypomagnesemia

¹Characteristics and outcome data for 17 patients cohort, including 5 patients that received CTH.

M: Man; W: Women; ADR: Adverse drug reaction; DSF: Disease-free survival; PFS: Progression-free survival, OS: Overall survival; NS: Not specified; NA: Not available; FU-LV: 5-flurouracil-leucovorin; PD: Progressive disease; SD: Stable disease; PR: Partial Response; SBRT: Stereotactic body irradiation; CR: Complete response.